Technology

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Published

2 hours ago

June 11, 2026

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven’s common stock. In addition, Enliven intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley and Barclays are acting as joint book-running managers for the proposed offering. Mizuho is also acting as a book-running manager and LifeSci Capital is acting as a passive book-running manager for the proposed offering.

The offering is being made pursuant to a Registration Statement on Form S-3ASR, including a base prospectus, which became automatically effective upon filing with the U.S. Securities and Exchange Commission (SEC) on August 13, 2025, and Enliven will file a preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which can be accessed for free through the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.

About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Enliven within the meaning of the federal securities laws, including those related to the completion, timing, and size of the offering and Enliven’s intent to grant the underwriters a 30-day option to purchase additional shares. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: whether or not Enliven will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that Enliven files from time to time with the Securities and Exchange Commission, including the registration statement and the preliminary prospectus supplement relating to the public offering. These forward-looking statements are made as of the date of this press release, and Enliven assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants-302798527.html

SOURCE Enliven Therapeutics, Inc.

Technology

Thinkific to Hold Annual General Meeting on June 18, 2026

Published

42 minutes ago

June 11, 2026

(Virtual Only)

VANCOUVER, BC, June 11, 2026 /CNW/ – Thinkific Labs Inc. (“Thinkific” or the “Company”) (TSX: THNC), a leading learning commerce platform, will hold its Annual General Meeting, at 10:00 a.m. PT, Thursday, June 18, 2026, via live webcast (the “Meeting”).

Notice and Access and Record Date
Thinkific is using the notice-and-access procedures to deliver the Meeting materials to shareholders. Shareholders will have received a notice with instructions on how to access the Management Information Circular and related materials electronically, and how to request a paper copy if preferred.

The record date for determining shareholders entitled to receive notice of and to vote at the Meeting is April 30, 2026.

Registered shareholders and duly appointed proxyholders can attend the Meeting online at meetnow.global/MQDKXZY. Registered shareholders and duly appointed proxyholders can log in using a control number or invite code, as applicable, to participate, vote, or submit questions during the Meeting’s live webcast.

Shareholders are encouraged to vote in advance of the Meeting by submitting their proxy or voting instruction form by 11:00 a.m PT, Wednesday, June 18, 2025, the deadline indicated in the Meeting materials.

Guests are welcome to listen to the Meeting proceedings by registering at meetnow.global/MQDKXZY.

The Management Information Circular is available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

About Thinkific
Thinkific (TSX:THNC) is an award-winning learning commerce platform where courses and community come together to power business growth. Thinkific gives academies, experts, and businesses everything they need to create and sell online learning experiences, build communities, and grow their revenue — all from one platform. More than 35,000 customers — including companies like GoDaddy, Nasdaq, ActiveCampaign, and Datadog — have generated billions in revenue using Thinkific, impacting more than 200 million people worldwide.

For more information, please visit www.thinkific.com.

SOURCE Thinkific Labs Inc.

Technology

Cars.com Names Sarah Kettler Chief Marketing Officer

Published

43 minutes ago

June 11, 2026

Veteran marketplace leader with track record of scaling modern brands, driving demand and accelerating business performance joins executive team to help shape company’s next chapter

CHICAGO, June 11, 2026 /PRNewswire/ — Car-shopping marketplace Cars.com Inc. (NYSE: CARS) today announced the appointment of Sarah Kettler as Chief Marketing Officer, effective June 15, 2026. In her role, Kettler will oversee the company’s integrated marketing and communications organization, responsible for strengthening the brand, deepening customer engagement, driving growth and advancing the company’s long-term strategic objectives.

Kettler joins from SeatGeek, a ticketing technology marketplace, where she spent a decade leading marketing, most recently as Executive Vice President, Marketing & Communications. During her tenure, she built a performance marketing engine that doubled consumer awareness, strengthened platform value for buyers and sellers, and drove sustained growth — while capturing meaningful share in a crowded market. Prior to SeatGeek, Kettler held strategy and communications roles at WME-IMG and Deloitte Consulting.

“Sarah brings exactly the kind of experience we need at this moment,” said Tobi Hartmann, CEO of Cars.com. “She’s built and positioned marketplace brands, she understands the dynamics of connecting buyers and sellers at scale, and she knows how to translate brand strategy into real business growth. I’m confident she’ll be a strong force as we continue strengthening our position as the most trusted auto marketplace.”

Kettler added: “The opportunity to join Cars.com at this inflection point is incredibly compelling. We’re at an exciting moment where artificial intelligence and technology are rapidly changing how we can market, but the core of what Cars.com needs to do remains the same: Deliver confident shopping for consumers and enable efficient growth for dealers and OEMs. I look forward to building off the company’s strong foundation while helping drive the next chapter of growth.”

About Cars.com Inc.

Cars.com Inc. (NYSE: CARS) is a trusted audience-powered and data-driven technology platform that simplifies buying and selling cars. The flagship Cars.com marketplace connects millions of consumers to dealerships across the U.S., powering the car buying experience with artificial intelligence (“AI”) shopping tools and comprehensive vehicle reviews and content. Our interconnected ecosystem of products enables dealers and OEMs to sell more cars by efficiently leveraging our marketplace, dealer websites, trade and appraisal tools, and proprietary in-market media solutions. Learn more at www.carscommerce.inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/carscom-names-sarah-kettler-chief-marketing-officer-302798492.html

SOURCE Cars.com Inc.

Technology

Space Exploration Technologies Corp. Announces Filing of Final Prospectus in Connection with Initial Public Offering

Published

43 minutes ago

June 11, 2026

A supplemented PREP prospectus and any amendment will be accessible through SEDAR+ within two business days

STARBASE, Texas, June 11, 2026 /CNW/ – Space Exploration Technologies Corp. (“SpaceX”) today announced that, in connection with its initial public offering of shares of Class A common stock, it has received a receipt for a base PREP prospectus dated June 11, 2026 filed with the securities regulatory authorities in each of the provinces and territories of Canada and is accessible on SEDAR+ at www.sedarplus.ca.

A supplemented PREP prospectus containing pricing information and any amendment will be accessible within two business days under SpaceX’s profile on SEDAR+ at www.sedarplus.ca. Access to the supplemented PREP prospectus and any amendment is provided in accordance with securities legislation relating to procedures for providing access to a supplemented PREP prospectus and any amendment.

An electronic or paper copy of the base PREP prospectus, the supplemented PREP prospectus when available and any amendment may be obtained, without charge, from RBC Dominion Securities Inc., 180 Wellington Street West, 8th Floor, Toronto, ON M5J 0C2, Attn: Distribution Centre, or via email at Distribution.RBCDS@rbccm.com by providing an email address or address, as applicable.

No securities regulatory authority has either approved or disapproved the contents of this news release. This news release does not constitute an offer to sell or solicitation of an offer to buy any of these securities in any jurisdiction in which the offering or sale is not permitted. This press release does not provide full disclosure of all material facts relating to the securities offered. In Canada, the offering is only made by prospectus. Investors should read the base PREP prospectus, the supplemented PREP prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

United States

A registration statement relating to the Class A common stock was declared effective by the Securities and Exchange Commission on June 11, 2026. This offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 866-471-2526 or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; BofA Securities, Inc., Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at dg.prospectus_requests@bofa.com; Citigroup Global Markets, Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by telephone at 1-800-831-9146; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

About SpaceX

Founded in 2002, SpaceX is the only company building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. At our core, we are builders. We design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft.

SOURCE Space Exploration Technologies Corp.